RET and medullary thyroid gland carcinoma: The heightened levels of VEGF and its receptor, VEGFR, observed in MTC, especially in tumors with RET mutations, reinforce the therapeutic rationale for the use of MKIs, alternatively termed anti-angiogenic medications, in the clinical management of advanced-stage MTC.